DELIVERY DEVICE AND METHOD
A nasal delivery device for and method of delivering substance to the middle meatus in a nasal cavity of a subject in the treatment of a condition, in particular an inflammatory or infectious condition, thereof, the delivery device comprising: a nosepiece unit including a nosepiece for fitting to a nostril of a subject and a nozzle through which substance is in use delivered to the respective nasal cavity; and a delivery unit for delivering substance through the nozzle of the nosepiece; wherein the delivery device is configured to provide for deposition of a significant fraction of the delivered dose on, around and in the vicinity of the middle meatus.
1 - 252 . (canceled)
253 . A method of treating chronic rhinosinusitis with or without nasal polyps in a subject in need thereof by delivering doses of fluticasone into a nasal cavity of the subject, the method comprising:
inserting a nosepiece of a delivery device into a first nostril of the subject, the nosepiece including a nozzle;
inserting a mouthpiece of the delivery device into an oral cavity of the subject;
establishing a first flow of exhalation breath into the mouthpiece while the nosepiece is inserted into the first nostril to cause closure of an oropharyngeal velum of the subject; and
manually actuating a delivery pump of the delivery device to release a first dose of fluticasone through the nozzle and to release at least a portion of the first flow of exhalation breath out of the nosepiece;
wherein the nosepiece extends into the first nostril and is configured to expand a first nasal valve of the subject; and
wherein at least 50% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve and at least 30% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve and above a first inferior meatus of the subject.
254 . The method of claim 253 , wherein at least 55% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve.
255 . The method of claim 254 , wherein at least 60% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve.
256 . The method of claim 255 , wherein at least 65% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve.
257 . The method of claim 256 , wherein at least 70% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve.
258 . The method of claim 253 , wherein at least 35% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve and above the first inferior meatus of the subject.
259 . The method of claim 258 , wherein at least 40% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve and above the first inferior meatus of the subject.
260 . The method of claim 259 , wherein at least 50% of the first dose of fluticasone as initially deposited is deposited in a region of the nasal cavity which is posterior of the first nasal valve and above the first inferior meatus of the subject.
261 . The method of claim 253 , further comprising removing the nosepiece from the first nostril of the subject.
262 . The method of claim 261 , further comprising:
inserting the nosepiece into a second nostril of the subject;
establishing a second flow of exhalation breath into the mouthpiece while the nosepiece is inserted into the second nostril to cause closure of the oropharyngeal velum of the subject; and
manually actuating the delivery pump of the delivery device to release a second dose of fluticasone through the nozzle of the delivery pump and to release at least a portion of the second flow of exhalation breath out of the nosepiece;
wherein the nosepiece extends into the second nostril and is configured to expand a second nasal valve of the subject; and
wherein at least 50% of the second dose of fluticasone as initially deposited is deposited in a region which is posterior of the second nasal valve and at least 30% of the second dose of fluticasone as initially deposited is deposited in a region which is posterior of the second nasal valve and above a second inferior meatus of the subject.
263 . The method of claim 262 , wherein at least 55% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior of the second nasal valve.
264 . The method of claim 263 , wherein at least 60% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior of the second nasal valve.
265 . The method of claim 264 , wherein at least 65% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior of the second nasal valve.
266 . The method of claim 265 , wherein at least 70% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior of the second nasal valve.
267 . The method of claim 262 , wherein at least 35% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior to the second nasal valve and above the second inferior meatus of the subject.
268 . The method of claim 267 , wherein at least 40% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior to the second nasal valve and above the second inferior meatus of the subject.
269 . The method of claim 268 , wherein at least 50% of the second dose as initially deposited is deposited in a region of the nasal cavity which is posterior to the second nasal valve and above the second inferior meatus of the subject.
270 . The method of claim 253 , wherein the delivery pump is a multi-dose pump configured to deliver a plurality of doses of fluticasone.
271 . The method of claim 253 , wherein the nozzle provides for delivery of an aerosol spray having a cone angle of not more than about 50 degrees.
272 . The method of claim 253 , wherein the nozzle provides for delivery of a liquid spray.